MedPath

Efficacy and Safety of Sodium Benzoate in the Management of Hyperammonemia in Infants, Children and Adolescent With Chronic Liver Disease.

Not Applicable
Completed
Conditions
Chronic Liver Disease
Interventions
Other: Powdered table sugar as palcebo
Registration Number
NCT04022941
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Brief Summary

Subject will be randomize in two groups. Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5days.Since the dosage of Sodium Benzoate is Sta t250mg/Kg and then 250mg/Kg in next 24 hours, each patient would be given 750mg /kg stat and 750mg /kg in next 24 hours,keeping in view that 2/3 of powder used would be powdered sugar in the intervention arm. The dose of the powder used would be doubled in case of the ammonia level more than 300 mcg/dl. The drug will be prepared in sterile water and administered per orally or via the nasogastric tube. All the enrolled patients would be treated with SMT as per the recommendations of the EASL/AASLD 2014 guidelines of management of hepatic encephalopathy.

Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
108
Inclusion Criteria
  • Infants, children and adolescents under 18 years of age with decompensated Chronic liver disease with hyperammonemia < 400 mcgm and /dl.
Exclusion Criteria
  1. Patients who have received sodium benzoate within 1 week priorto evaluation.
  2. Baseline serum sodium above 155 mEq/L
  3. Patients with Grade 3 ascites as per IAC classification.
  4. Patients who did not give a written informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPowdered table sugar as palceboGroup B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
Sodium BenzoateSodium BenzoateGroup A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5days.
Primary Outcome Measures
NameTimeMethod
Change in the blood ammonia levels at 5 days of starting therapy in both groups.Day 5
Secondary Outcome Measures
NameTimeMethod
Proportion of children with hypernatremia in both groups.Day 90
Proportion of children with worsening ascites in both groups.Day 90
Duration of hospital stay in both groups.Day 90
Proportion of children with metabolic acidosis in both groups.Day 90
Short term survival with native liver in both groupsDay 90
Change in the grading of Hepatic Encephalopathy in both groups.Day 90

Trial Locations

Locations (1)

Institute of Liver & Biliary Sciences

🇮🇳

New Delhi, Delhi, India

© Copyright 2025. All Rights Reserved by MedPath